Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

about

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

Item

http://www.wikidata.org/entity/Q42516732

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

@en

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

@nl

type

Item

label

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

@en

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

@nl

prefLabel

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

@en

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

@nl

P1476

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS

@en

P2093

Eulalia Rodríguez-Martín

http://www.w3.org/2001/XMLSchema#string

José C Álvarez-Cermeño

http://www.w3.org/2001/XMLSchema#string

Lucienne Costa-Frossard

http://www.w3.org/2001/XMLSchema#string

Noelia Villarrubia

http://www.w3.org/2001/XMLSchema#string

Raquel Alenda

http://www.w3.org/2001/XMLSchema#string

Susana Sainz de la Maza

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

Multiple sclerosis-a quiet revolution

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Interleukin 17F level and interferon β response in patients with multiple sclerosis.

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

Expanded CD8 T-cell sharing between periphery and CNS in multiple sclerosis.

Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.

P2888

s00415-017-8625-6

P304

24-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00415-017-8625-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

265

http://www.w3.org/2001/XMLSchema#string

P50

Luisa M Villar

C Espejo

María I Domínguez-Mozo

Roberto Alvarez-Lafuente

Jordi Rio

Xavier Montalban

P577

2017-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29027004

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte